Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease.

Cannas G, Poutrel S, Thomas X.

Mediterr J Hematol Infect Dis. 2017 Feb 15;9(1):e2017015. doi: 10.4084/MJHID.2017.015. eCollection 2017. Review.

2.

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.

Stallworth JR, Jerrell JM, Tripathi A.

Am J Hematol. 2010 Oct;85(10):795-7. doi: 10.1002/ajh.21772.

3.

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.

Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.

Pediatr Hematol Oncol. 1999 May-Jun;16(3):221-32.

PMID:
10326220
4.

Advances in the use of hydroxyurea.

Ware RE, Aygun B.

Hematology Am Soc Hematol Educ Program. 2009:62-9. doi: 10.1182/asheducation-2009.1.62. Review.

PMID:
20008183
5.

Hemorheological risk factors of acute chest syndrome and painful vaso-occlusive crisis in children with sickle cell disease.

Lamarre Y, Romana M, Waltz X, Lalanne-Mistrih ML, Tressières B, Divialle-Doumdo L, Hardy-Dessources MD, Vent-Schmidt J, Petras M, Broquere C, Maillard F, Tarer V, Etienne-Julan M, Connes P.

Haematologica. 2012 Nov;97(11):1641-7. doi: 10.3324/haematol.2012.066670. Epub 2012 Jun 11.

6.

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.

JAMA. 2003 Apr 2;289(13):1645-51. Erratum in: JAMA. 2003 Aug 13;290(6):756.

PMID:
12672732
7.

Hydroxyurea for the treatment of sickle cell disease.

Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, Wilson RF, Bass EB, Lanzkron S.

Evid Rep Technol Assess (Full Rep). 2008 Mar;(165):1-95. Review.

8.

Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.

Blood. 1999 Sep 1;94(5):1550-4.

9.

Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease.

Krishnamoorthy P, Alyaarubi S, Abish S, Gale M, Albuquerque P, Jabado N.

Pediatrics. 2006 Aug;118(2):e537-9.

PMID:
16882790
10.
11.

[Effect of hydroxyurea on hemoglobin S].

Torres AF, Eberle SE, Sciuccati G, Bonduel M.

Medicina (B Aires). 2003;63(2):140-2. Spanish.

PMID:
12793083
12.

Emerging drugs for sickle cell anemia.

Singh PC, Ballas SK.

Expert Opin Emerg Drugs. 2015 Mar;20(1):47-61. doi: 10.1517/14728214.2015.985587. Epub 2014 Nov 27. Review.

PMID:
25431087
13.

How I use hydroxyurea to treat young patients with sickle cell anemia.

Ware RE.

Blood. 2010 Jul 1;115(26):5300-11. doi: 10.1182/blood-2009-04-146852. Epub 2010 Mar 11. Review.

14.

Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.

Rogers ZR.

Semin Hematol. 1997 Jul;34(3 Suppl 3):42-7.

PMID:
9317200
15.

Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J.

JAMA. 2014 Sep 10;312(10):1033-48. doi: 10.1001/jama.2014.10517. Review. Erratum in: JAMA. 2014 Nov 12;312(18):1932. JAMA. 2015 Feb 17;313(7):729.

PMID:
25203083
16.

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.

Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC; DOVE Investigators.

N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021. Epub 2015 Dec 8.

17.

Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease.

Wang WC.

Exp Biol Med (Maywood). 2016 Apr;241(7):730-6. doi: 10.1177/1535370216642048. Epub 2016 Mar 29. Review.

18.

Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.

Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE; Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH).

Am J Hematol. 2013 Nov;88(11):932-8. doi: 10.1002/ajh.23547. Epub 2013 Aug 30.

19.

[Sickle cell anemia in children: value of hydroxyurea in severe forms].

Oury AP, Hoyoux C, Dresse MF, Chantraine JM.

Arch Pediatr. 1997 Sep;4(9):839-44. French.

PMID:
9345564
20.

Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia.

Darbari DS, Nouraie M, Taylor JG, Brugnara C, Castro O, Ballas SK.

Eur J Haematol. 2014 Apr;92(4):341-5. doi: 10.1111/ejh.12245. Epub 2014 Jan 30.

Supplemental Content

Support Center